BeStock  
Stocks › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2565Biotechnology
$22.80 −$0.40 (-1.72%)
Pre-market · Oct 6, 8:40 am ET · After hours $22.80 0.00%
Open$22.84
Prev close$23.20
Day range$22.23 – $23.34
Volume1.18M
Market cap$2.73B
P/E (TTM)–
Dividend yield–

NAMS Stock News

Headlines matching NewAmsterdam Pharma or the NAMS ticker, most recent first.

  • Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50Market news · 8 Sep 2026
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket news · 8 Sep 2026
  • H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52Market news · 30 Sep 2026
  • BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58Market news · 22 Sep 2026
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57Market news · 22 Sep 2026
  • William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket news · 18 Sep 2026
  • Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48Market news · 8 Aug 2026
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52Market news · 7 Aug 2026
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58Market news · 6 Aug 2026
  • Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60Market news · 4 Aug 2026
  • BMO Capital Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $58Market news · 21 Jul 2026
  • RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51Market news · 30 Jun 2026
  • Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45Market news · 8 May 2026
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $45 to $48Market news · 8 May 2026
  • H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)TipRanks · 8 May 2026

Discussion

No comments yet — be the first to weigh in on NAMS.

Leave a comment

Scroll to Top